Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Disulfiram (HB1119)
Description:Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor.
Purity:>97%
Doxycycline hyclate (HB4608)
Description:Broad-spectrum antibiotic. Used in inducible Tet-on/ Tet-off gene expression systems for gene editing.
Purity:>95%
Minocycline hydrochloride (HB4617)
Description:Broad spectrum antibiotic. Potent microglial activation inhibitor. Allows formation of EPSs.
Purity:>98%